Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

55
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
55
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assays.

Blood advances·2026
Same author

Evaluation of the analytical performance of the Optilite<sup>®</sup> on lipoprotein(a) measurement.

Clinical chemistry and laboratory medicine·2026
Same author

Anti-heparanase shields against endothelial dysfunction in a rat model of warm pulmonary ischemia-reperfusion.

Respiratory research·2026
Same author

Performance evaluation of Stago sthemO 301 hemostasis analyzer for routine testing, coagulation factors, and inhibitors.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same author

The phosphatase activity of soluble epoxide hydrolase regulates vascular calcification through the metabolism of pyrophosphate anions.

Cell death & disease·2025
Same author

[Hemolysis index: qualification and evaluation of usefulness in patients on ECMO].

Annales de biologie clinique·2025

Related Experiment Video

Updated: Oct 11, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Factor XII deficiency evaluated by thrombin generation assay.

Guillaume Feugray1, Fiston Kasonga2, Pierre Chamouni3

  • 1Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Clinical Biochemistry
|November 29, 2021
PubMed
Summary

Coagulation factor XII (FXII) deficiency does not significantly alter thrombin generation profiles. However, thrombin generation assay (TGA) can differentiate bleeding versus thrombotic tendencies in FXII deficiency patients.

Keywords:
BleedingFactor XII deficiencyThrombin generation assay

More Related Videos

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

965
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.0K

Related Experiment Videos

Last Updated: Oct 11, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

965
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.0K

Area of Science:

  • Hematology
  • Hemostasis and Thrombosis

Background:

  • Coagulation factor XII (FXII) is implicated in thrombin generation and other physiological processes.
  • Unlike other coagulation factors, FXII deficiency is not typically associated with an increased bleeding risk.

Purpose of the Study:

  • To investigate modifications in thrombin generation assay (TGA) profiles in individuals with FXII deficiency.
  • To assess the correlation between TGA results and the severity of FXII deficiency.
  • To compare TGA profiles in FXII deficiency, healthy controls, and hemophilia A.

Main Methods:

  • Thrombin generation assay (TGA) was performed on platelet-poor plasma (PPP) using standardized concentrations of tissue factor and phospholipids.
  • TGA profiles were analyzed in 54 patients with FXII deficiency (categorized by activity levels), 25 healthy controls, and 23 patients with factor VIII (FVIII) deficiency.

Main Results:

  • A correlation was observed between FXII deficiency and activated partial thromboplastin time (aPTT).
  • Thrombin generation was decreased in healthy controls and all FXII deficiency groups.
  • Patients with FVIII deficiency exhibited reduced endogenous thrombin potential (ETP), peak thrombin, and velocity compared to those with FXII deficiency.

Conclusions:

  • Thrombin generation profiles were found to be insensitive to FXII deficiency itself.
  • TGA demonstrated potential in distinguishing between bleeding and thrombotic tendencies in patients with FXII deficiency.
  • These findings are exploratory and require further confirmation.